This will be a randomized, double-blinded, three-period crossover study of platelet activation and aggregation in 30 non-smoking healthy volunteers comparing chlorthalidone (CTD), hydrochlorothiazide (HCTZ), and aspirin (ASA; active control). The study hypothesis is that CTD has different effects on platelet activation and aggregation than HCTZ.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
30
Creighton University
Omaha, Nebraska, United States
RECRUITINGChange in mean fluorescence intensity of PAC-1
The primary endpoint for this study will be the change in mean fluorescence intensity (MFI) of the platelet activation marker PAC-1 due to HCTZ, CTD, and aspirin.
Time frame: 2 weeks
Change in CD62P expression
Change in platelet expression of CD62P (p-selectin) in response to CTD, HCTZ, and ASA.
Time frame: 2 weeks
Change in platelet aggregation
Change in platelet aggregation measured by flow cytometry in response to CTD, HCTZ, and ASA
Time frame: 2 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.